Log In
Print
BCIQ
Print
Print this Print this
 

APD403

  Manage Alerts
Collapse Summary General Information
Company Acacia Pharma Ltd.
DescriptionIV formulation of amisulpride, an off-patent dopamine D2 and D3 receptor antagonist
Molecular Target Dopamine D2 receptor ; Dopamine D3 receptor (DRD3)
Mechanism of ActionDopamine D2 receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationEmesis
Indication DetailsTreat and prevent chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today